A Phase I/IIA Study of PF-07104091 to Treat Advanced Ovarian Cancer


Full Title

Phase 1/2a Dose Escalation, Finding and Expansion Study Evaluating Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Anti Tumor Activity of PF-07104091 as a Single Agent and In Combination Therapy


The purpose of this study is to assess the safety and effectiveness of the investigational drug PF-07104091 to treat advanced ovarian cancer that has come back or continued to grow despite treatment. PF-07104091 blocks certain proteins, called CDKs, that are required for cancer cells to divide. It is taken orally (by mouth).

Who Can Join

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have advanced ovarian cancer that came back or continued to grow despite treatment that included a platinum-containing drug.
  • At least 4 weeks must pass since the completion of chemotherapy and 3 weeks since radiation therapy or major surgery and receipt of PF-07104091.
  • Patients must be physically well enough that they are able to be mobile, take care of themselves, and engage in all but physically strenuous activities. For example, they must be well enough that they could carry out office work or light housework.
  • This study is for women age 18 and older.

For more information and to ask about eligibility for this study, please contact the office of Dr. Rachel Grisham at 646-888-4653.







ClinicalTrials.gov ID